Tagged with Bayer

Germany Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward cell and gene therapies to bolster its development pipeline and create transformative biotechnological solutions.   German pharmaceutical company Bayer AG is setting its sights on…

Bayer Tomer Feffer, Country Division Head Scandinavia & MD Bayer Sweden, shares his enthusiasm for Sweden’s innovative spirit and how Bayer is leveraging it through partnerships with medical technology and digital health startups. He also talks about the strategic importance of Sweden for Bayer as an early adopter of new technologies,…

Spain Against an alluring backdrop, big-name pharma brands are now starting to spend heavily on in-country manufacturing, development and shared service facilities in Spain.   Spain has exceedingly high youth unemployment. However, the country simultaneously possesses some of the best business universities, technical schools and hospitals. This means that it is…

Spain Following Bayer’s acquisition of Monsanto, a US agriculture giant, the company is facing a new era in which its pharmaceutical arm is still a highly strategic part. Bernardo Kanahuati, Bayer’s CEO for Iberia, highlights the importance of Spain’s manufacturing and R&D for Bayer International, as well as his strategy to…

UK The UK country managers of some of the biggest global pharma companies explain what it takes to manage in the UK market.   Erik Nordkamp, Pfizer Erik Nordkamp, the Dutch national serving as managing director of Pfizer UK and the newly-appointed president of the ABPI, likens managing a UK affiliate…

UK After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting exciting Phase III developments and introducing the new Baylab opened by Bayer in Reading (near London).   It is this…

Portugal The top 20 pharma companies in Portugal ranked by sales and market share for the year leading up to March 2018. MSD leads the way with EUR 148 million in sales and a 5.4 percent market share, followed by Mylan and Bayer.

Ecuador The top 20 pharma companies in Ecuador in 2017, ranked by value, for both the retail and public markets. Argentinian firm Roemmers leads the way in the retail market, followed by global players Bayer and Sanofi. In terms of Ecuador’s public market, the top three companies are global giants Roche,…

Portugal Florian Ibe, managing director at Bayer Portugal, discusses market access hurdles, as well as Portugal’s expertise in scientific and clinical research and highly educated workforce. In three years of his tenure, Bayer has returned to growth, brought the global innovation portfolio to Portuguese patients and healthcare professionals in areas such…

Poland The Top 20 pharma companies in the Polish retail market for 2017 ranked by sales in USD millions. Domestic champion Polpharma leads the way, followed by international players Teva and Bayer.

Portugal A new regulation is helping Portugal’s market access conditions for pharmaceuticals catch up with those of other developed European markets, with a jump in the number of approvals for 2017. The situation is further enhanced by increasing inter-stakeholder communication and transparency, and a targeted focus on removing bureaucracy barriers, from…

Bulgaria Ekaterina Karpuzova, country commercial lead pharmaceuticals at Bayer Bulgaria, explains how the national healthcare system has evolved over the last few years as well as demonstrates the commitment of Bayer Bulgaria to supporting the impact and quality of its solutions through value-based evidence. After starting in Bayer Bulgaria, you went…